{"publication_id":"a3bbb329-ee5b-47f5-b797-dd3b6fd29757","traces":[{"claim_id":"claim_1","claim":"Across 4 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of serious heart failure events and related cardiovascular composite outcomes in patients with type 2 diabetes and/or heart failure. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_3","claim":"The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_4","claim":"`fact_id=150888` (`A_core`) — SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% doi=10.1002/ejhf.1732","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_5","claim":"`fact_id=156141` (`A_core`) — empagliflozin significantly decreases the mortality rate from cardiovascular causes [38% relative risk reduction (RRR)] doi=10.1186/s12933-018-0745-5","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_6","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_7","claim":"`fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_8","claim":"`fact_id=193807` (`A_core`) — Canagliflozin reduced the risk of the primary composite outcome by 30% compared to placebo doi=10.4093/dmj.2025.0220","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_9","claim":"Treat this as a receipt map for choosing the next extraction, not as evidence that the topic has one unified effect. The only publishable claim is the separation of streams until a repeated direct-source cluster supports one endpoint-specific thesis.","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]},{"claim_id":"claim_10","claim":"_No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._","candidate_sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","url":"https://pubmed.ncbi.nlm.nih.gov/32037659/"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":"https://pubmed.ncbi.nlm.nih.gov/29991346/"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":"https://pubmed.ncbi.nlm.nih.gov/27470878/"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":"https://pubmed.ncbi.nlm.nih.gov/27296042/"}]}]}